Want to see GB:IMM full AI Analyst Report?
Top Page
ImmuPharma
(LSE:IMM)
Select Model
Select Model
Rating:41Neutral
Price Target:
3.50 p
▼(-43.55% Downside)
Action:Reiterated
Date:05/28/26
The score is primarily constrained by weak financial performance (no revenue, continued losses and cash burn, and a fragile equity position), partially offset by low debt. Technicals add modestly negative pressure due to a weak longer-term trend and bearish MACD, while valuation cannot be meaningfully supported with the provided P/E and missing dividend yield.
Positive Factors
Low leverage
Minimal reported debt materially reduces ongoing interest burden and refinancing pressure for a clinical-stage biotech. This structural strength gives management flexibility to fund R&D through equity, partnerships, or grants without near-term covenant or interest risks, supporting program continuity.
Negative Factors
No revenue generation
Absence of product or recurring revenue forces full reliance on external financing, partnerships, or milestone payments. That structural dependence increases dilution and execution risk, because sustained operations hinge on successful clinical progress or deal-making rather than internal cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Minimal reported debt materially reduces ongoing interest burden and refinancing pressure for a clinical-stage biotech. This structural strength gives management flexibility to fund R&D through equity, partnerships, or grants without near-term covenant or interest risks, supporting program continuity.
Read all positive factors
ImmuPharma (IMM) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£25.27M
Dividend YieldN/A
Average Volume (3M)15.00M
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue GrowthN/A
EPS Growth36.67%
CountryUK
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding623,911,400
10 Day Avg. Volume4,827,745
30 Day Avg. Volume14,996,625
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)44.28
Price to Sales (P/S)0.00
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ImmuPharma Business Overview & Revenue Model
Company Description
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lea...
How the Company Makes Money
Revenue model details sufficient to describe how ImmuPharma currently makes money (e.g., recurring product sales, disclosed licensing/royalty income, or specific collaboration payments) are null based on the information available here. As a clinic...
ImmuPharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 118.35K |
| Gross Profit | -35.30K | -63.88K | -37.61K | -118.00K | 118.35K |
| EBITDA | -2.51M | -2.61M | -3.02M | -2.91M | -8.70M |
| Net Income | -1.81M | -2.48M | -2.92M | -3.81M | -8.17M |
Balance Sheet | |||||
| Total Assets | 1.88M | 977.01K | 2.72M | 3.97M | 6.00M |
| Cash, Cash Equivalents and Short-Term Investments | 1.35M | 236.90K | 208.48K | 667.81K | 1.65M |
| Total Debt | 0.00 | 0.00 | 0.00 | 111.00 | 700.00 |
| Total Liabilities | 1.19M | 1.52M | 1.67M | 1.45M | 1.58M |
| Stockholders Equity | 686.86K | -542.86K | 1.06M | 2.52M | 4.41M |
Cash Flow | |||||
| Free Cash Flow | -2.37M | -1.77M | -1.36M | -2.45M | -4.88M |
| Operating Cash Flow | -2.37M | -1.77M | -1.36M | -2.35M | -4.83M |
| Investing Cash Flow | 6.91K | 1.29M | 188.76K | -77.42K | -50.28K |
| Financing Cash Flow | 3.43M | 500.02K | 722.10K | 1.55M | 702.05K |
ImmuPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | £42.66M | -6.77 | -55.47% | ― | ― | 19.83% | |
53 Neutral | £137.51M | -24.91 | 90.29% | ― | ― | 69.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £31.87M | -6.46 | -284.01% | ― | ― | -105.65% | |
47 Neutral | £25.27M | -54.17 | -5.25% | ― | 95.16% | 85.60% | |
42 Neutral | £52.36M | -3.51 | -2807.75% | ― | ― | -28.29% | |
41 Neutral | £25.27M | -10.00 | -1397.43% | ― | ― | 36.67% |
* Healthcare Sector Average
GB:IMM
ImmuPharma
3.70
1.65
80.49%
GB:SAR
Sareum Holdings
23.50
5.50
30.56%
GB:SCLP
Scancell Holdings
13.20
2.85
27.54%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
775.00
644.25
492.73%
GB:SBTX
SkinBioTherapeutics
9.75
-6.75
-40.91%
GB:POLB
Poolbeg Pharma Ltd.
6.30
3.30
110.00%
ImmuPharma Corporate Events
Business Operations and StrategyShareholder Meetings
ImmuPharma shareholders back all resolutions at 2026 AGM
Positive
Jun 25, 2026
ImmuPharma reported that all six resolutions at its 2026 annual general meeting were approved by shareholders, including the receipt of 2025 accounts, reappointment of a director and the auditor, and authorisations related to share allotment. Inve...
Business Operations and StrategyProduct-Related Announcements
ImmuPharma taps Bachem to manufacture Kapiglucagon API for Type 1 diabetes program
Positive
Jun 25, 2026
ImmuPharma has selected Swiss-based Bachem AG as its active pharmaceutical ingredient manufacturing partner for Kapiglucagon, marking a key Chemistry, Manufacturing and Controls milestone for the Type 1 diabetes program. The move strengthens the s...
Business Operations and Strategy
ImmuPharma flags early-stage P140 glioblastoma research while reaffirming autoimmune focus
Positive
Jun 24, 2026
ImmuPharma has highlighted early-stage research from the University of Murcia, published in the journal Autophagy, indicating potential applications of its P140 peptide in glioblastoma, an aggressive brain cancer. The company has been following th...
Business Operations and StrategyExecutive/Board Changes
ImmuPharma flags Incanthera board shake-up as chairman steps down
Neutral
Jun 4, 2026
ImmuPharma PLC has highlighted a corporate update from partner company Incanthera plc, noting that Tim McCarthy has stepped down as Executive Chairman of Incanthera as part of wider board changes. The announcement, issued via a non-regulatory comm...
Financial DisclosuresShareholder Meetings
ImmuPharma Sets June AGM as 2025 Annual Report Reaches Shareholders
Neutral
Jun 2, 2026
ImmuPharma PLC has dispatched its Notice of Annual General Meeting and the Annual Report and Accounts for the year ended 31 December 2025 to shareholders, with electronic versions to be made available on the company’s website. The AGM is sch...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
ImmuPharma Narrows Loss, Raises Funds as P140 Autoimmune Platform Advances
Positive
May 27, 2026
ImmuPharma reported a narrowed loss of £1.8m for 2025, stable operating costs and a year-end cash balance of £1.4m, subsequently bolstered by a £6.47m equity raise in April 2026 to support its pipeline. The company advanced its P140...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
ImmuPharma Advances Kapiglucagon Diabetes Program With IND-Enabling Plan
Positive
May 5, 2026
ImmuPharma has initiated IND-enabling activities for its Kapiglucagon program, a proprietary glucagon prodrug for Type 1 diabetes, after signing a work order with specialist consultancy tranScrip. The partner will help shape regulatory strategy an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.